A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome

Affiliations

• ¹ Malignant Hematology Department, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Rami.Komrokji@moffitt.org.
• ² Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
• ³ Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine University Dusseldorf, Universitätsklinikum, Dusseldorf.
• ⁴ NCT/UCC-ECTU, Medical Faculty Carl Gustav Carus, Technical University, Dresden.
• ⁵ Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT.
• ⁶ Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.
• ⁷ Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss.
• ⁸ Department of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL.